Dyslipidaemia

Role of Genetic Testing in Management of Dyslipidemia

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Managing the Recurrent ASCVD Risks of Your ACS Patient: Gulf Perspective (Part 1)

APSC Consensus Recommendations on Dyslipidemia

ESC Lp(a) in Clinical practice EAS Consensus statement

CV Risk management in T1DM using guidelines

Event rates and Risk Factors for Recurrent CV Events

Public health recommendations for Lp(a) measurement

Single-Pill Combinations in Dyslipidemia

This review describes the potential benefits of combination treatment and presents data supporting the use of single-pill combination (SPC) for increasing exposure to lipid-lowering treatment (LLT).

The European experience: Swedeheart and AIFA registries

Highlights on the most recent real-world data on the use of PCSK9 inhibitors, including those from the Swedeheart and AIFA registries.

Statin/Ezetimibe Combination VS Statin Monotherapy

Use of Lipid-Lowering Therapies Over 2 Years

Why compromise for less: Should PCSK9 inhibitors be initial therapy?

What do us physicians and patients think about LLTs and goals of treatment?

Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice

Should we encourage earlier and broader use of combination therapies in dyslipidemia?

PCSK9i and Prevention of CVD

The synopsis of a Cochrane Systematic review on PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

PCSK9 Inhibitors in Cardiovascular Disease

PCSK9i after hospital discharge for acute MI

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines

LLTs and Antithrombotic Therapy in PAD

LLTs Exposure Time and Major Vascular Risk Reduction

Possible Challenges Post One Year of ESC/EAS Guidelines

Prognostic impact of achieving LDL cholesterol guidelines

Perceptions and Barriers on the use of PCSK9 inhibitors

LDL-C The Only Causal Risk Factor for ASCVD

Why low-density lipoprotein-cholesterol, the only causal risk factor for atherosclerotic cardiovascular disease, is still overlooked and underestimated.

LDL-C Targets in Patients with Heterozygous Familial Hypercholesterolemia

PCSK9 Inhibitors in Real World Practice

Relationship Between LDL-C LLTs and Risk of Stroke

ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci

Approach for Patients with PAD and T2D: Focus on LDL-C Control

Approach for Patients with CAD: Focus on LDL-C Control

Lipid Management in Patients with Diabetes Mellitus

Dyslipidemia performance of 2016 2019 and 2021 ESC Dyslipidemia guidelines

Act Now for Your ACS Patients: Optimize Your ACS Pathway

Lp(a) as ASCVD risk factor

The role of the patient in Achieving LDL-C Target

Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients

Cardiovascular diseases (CVDs) are the leading cause of death globally¹

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths¹. Of these deaths, 85% were due to myocardial infarction or stroke¹. A CV event is a highly traumatic experience for patients and their families². It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life^3,4.

EAS guidance regarding combining Lipid-modifying therapy

The ROSETTE Study

Atherosclerotic Cardiovascular Disease Risk Assessment

Regulate LDL-C level for those undergoing coronary revascularization (Diabetic Patients)

Achievement of ESC/EAS LDL-C Treatment Goals After an ACS with Statin and Alirocumab

Clinical practice experience in patients with familial hypercholesterolemia (FH) from the Safeheart registry

Proprotein convertase subtilisin/kexin type 9 inhibitors for heterozygous familial hypercholesterolemia: A clinical practice experience from the Safeheart registry

Odyssey outcomes - total events results

Optimal use of LLT after ACS

Odyssey outcomes - PVD results